Elekta致力于癌症护理的发展。bob体育网赌该公司提供正在进行的专业教育奖,并鼓励采用标准来支持多组分系统的互操作性。了解有关我们目前的计划汇总的更多信息。
ELEKTA可以通过包括提供研究资金,信息,访问研究硬件和/或软件的机制来支持调查员启动的研发协议项目,并访问其他ELEKTA资源。在交换中,Elekta预计以信息的形式受益,获得知识产权和研究结果,您的工作产品是您的工作产品。
Elekta拥有悠久而丰富的支持调查员启动的研究,导致技术和临床护理的进步。我们依靠与他们各自领域的领导者的调查人员密切合作关系。我们的联合研究努力的这些关系和结果是我们行业成功和领导的关键。
In order to maintain the highest standards, we have formulated a process to guide applicants through the research application. This process is intended to result in a well-defined and high quality research program that is mutually beneficial.
Elekta的研究合作计划根据国际和美国联邦法规,管理医疗保健制造商提供的研究资金到医疗保健提供者。该计划符合Elekta行为准则那Medical Imaging and Technology Alliance (MITA) Code of Ethics on Interactions with Healthcare Professionals, 这Compliance Program Guidance for Pharmaceutical Manufacturersfrom the US Office of Inspector General, and US Federal and国家阳光向医生报告付款。
ELEKTA可以通过包括以下各种机制支持调查员启动的研究和开发协议项目:
您的工作将以信息形式,获取知识产权,研究结果等的elekta。
To apply for a research grant, please complete the application form. To request a grant application form, please email your request toscientific.research@elekta.com.。
本申请已从美国国家卫生申请制定,可能对您熟悉。申请应专注,可实现,并没有过于雄心勃勃。请注意,Elekta可以享受高价值,具有明确界定的目标和任务,符合特定的里程碑并提供相关的可交付成果。应该清楚这些目标如何满足这些目标以及所达到的任务。还请将您的请求限制在完成项目所需的请求。
ELEKTA研究拨款计划旨在支持将推进知识和促进创新的临床和技术研究活动。应预期研究提案,展示临床创新,技术创新或商业化的强大潜力,与Elekta产品和临床解决方案有关的临床创新,包括立体定向体放射疗法(SBRT)的临床解决方案。
Elekta的研究委员会定期举行审查赠款申请。我们在收到完整的申请后的8-12周内,我们尽力回应您。如果批准,我们将与您合作,在Elekta和您的机构之间制定正式的研究协议。该项目仅在执行研究协议后开始。研究人员应预期这一事件的任何承诺。
In an effort to optimize the balance between direct research contributions and research overhead costs, Elekta has established a corporate policy to support a maximum funding level for Indirect Costs of 25%. This is consistent with, and in some cases in excess of Industry-wide funding levels as well as indirect funding levels of substantially larger research support programs that are not Industry-based.
For more information, please contact:scientific.research@elekta.com.。
Elekta places particular emphasis on research that advances the use of linear-accelerator based stereotactic body radiation therapy (SBRT) and stereotactic radiation therapy (SRT). Applications related to the use of linear accelerator based SBRT are strongly encouraged, and will be preferentially considered.
Elekta places particular emphasis on research that advances the use of linear-accelerator based stereotactic body radiation therapy (SBRT) and stereotactic radiation therapy (SRT). Applications related to the use of linear accelerator based SBRT are strongly encouraged, and will be preferentially considered.
The development of Stereotactic Body Radiation Therapy has evolved significantly over the last two decades. Today, SBRT is in common use for treatment of tumors in many anatomical sites. Strong belief that the technique has significant potential for improving outcomes and reducing costs is in part driving these efforts. Techniques and resultant outcomes, however, vary widely and there is still much to learn.
因此,Elekta正在促进努力推进对SBRT的理解,特别是与使用线性加速器技术涉及其交付。我们的近期研究和开发工作的大量比例将在SBRT上将,我们邀请我们的研究合作伙伴参加这些活动。我们的授予机制旨在促进这些努力,并鼓励指导这些目标的应用程序。
请参阅上面关于研究拨款和遵守国际和美国法规的一般信息的“研究授权”部分。您还将找到有关授予评估流程和ELEKTA政策的信息,以基于间接成本。
有关详细信息或要求赠款申请表,请发送电子邮件给您的请求scientific.research@elekta.com.。
ELEKTA的OpenRT认证计划建立了合规性,验证,部署和支持标准,以支持多组分系统的互操作性,并提高护理质量。
At Elekta, we believe that standards compliance and system-wide functionality are essential aspects of developing integrated tools to improve overall process efficiency. Elekta’s OpenRT Certification program establishes compliance, validation, deployment, and support standards to support the interoperability of multi-component systems and to enhance quality of care. With OpenRT Certification, customers can purchase the treatment planning system and the EMR/V&R system of their choice without worrying if the systems will work together.
The program ensures connectivity between the treatment planning system, Elekta's electronic medical record (EMR), and the linear accelerator by requiring vendors to transfer all of the data needed to effectively manage treatment planning, setup, and delivery.
通过OpenRT认证,在单个电话中提供技术支持。客户可以联系Elekta或其治疗计划供应商来解决出现的任何问题。
elekta想承认罗唆和飞利浦在他们努力加入我们建立计划以确保跨多个系统的互操作性。
请联系计划管理员,Leon Tomczyk,有关其他信息。
ELEKTA软件肿瘤学数据联盟(ODA)的使命是通过分析聚集肿瘤数据来改善患者癌症护理。bob体育网赌
肿瘤学数据联盟(ODA)的目标是通过分析聚集肿瘤学数据来改善患者癌症护理。bob体育网赌此数据联盟将是唯一的:
一如既往,ELEKTA将适用并设定质量数据标准,并将纳入当前客户的反馈,使其成为肿瘤治疗中心的独特和有价值的评估和研究工具。基准报告可以帮助我们目前的客户最大限度地提高对ELEKTA软件的投资。通过专注于官方发展援助的团队,将有一个专门的Elekta员工,可以帮助各个客户网站以及整个数据库的官方发展援助的质量保证和数据质量。这些基准报告将允许参与设施:
Each participant enters into a two-year renewable term and is asked to complete a minimum dataset requirement in order to maintain a high standard of quality. In addition, participating facilities will:
有关更多程序信息,请联系戴夫Eggert.
Elekta软件的日年计划注册商荣誉卓越的Elekta软件癌症注册商,为登记处的成功作出了宝贵的贡献,并扩大了对更广泛的设施和社区的贡献。bob体育网赌
Elekta赞助这个奖项,每年在AAN会议上展示。该奖项始于2009年,奖项是关于脑肿瘤的立体定向放射外科的最佳纸张。
每年elekta赞助了与肿瘤部分AAN和CNS的脑肿瘤相关的最佳纸张上最佳纸张奖。获奖者在AANS年会上呈现。
Elekta Software Registry客户通过直接从其注册软件从其注册软件的课程提交定期向Elekta Software的国家oncology数据库™(NODB)定期贡献数据。作为返回,Elekta软件通过互联网向贡献者提供专用的特定于贡献者的主要站点的聚合数据报告。Elekta软件的注册表客户可以使用此信息来生成年度报告,内部比较评估等等。
常常,Elekta被问及在专业文学中,专业会议海报或口腔演示文稿中使用我们的产品的正确方法。由于Elekta作为一个有机的实体和通过收购领先的行业公司及其产品,因此对适当的引用语言有相当困惑。
To demonstrate our commitment to the delivery of world class stereotactic solutions for linear accelerator users, Elekta introduces a program aimed at supporting our collaboration and research partners.